These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 8728771

  • 1. [Immunohistochemical analysis of p53 and c-erbB-2 in breast cancer].
    Castiglioni T, Elsner B, Curutchet HP, Montesinos M, Debonis D.
    Medicina (B Aires); 1995; 55(5 Pt 1):415-20. PubMed ID: 8728771
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
    McCann AH, Dervan PA, O'Regan M, Codd MB, Gullick WJ, Tobin BM, Carney DN.
    Cancer Res; 1991 Jun 15; 51(12):3296-303. PubMed ID: 1674898
    [Abstract] [Full Text] [Related]

  • 3. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF, Lopes AB, Nonogaki S, Soares FA, Netto MM, Nishimoto IN, Brentani MM.
    Oncol Rep; 2007 Jul 15; 18(1):121-6. PubMed ID: 17549356
    [Abstract] [Full Text] [Related]

  • 4. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.
    Ko SS, Na YS, Yoon CS, Park JY, Kim HS, Hur MH, Lee HK, Chun YK, Kang SS, Park BW, Lee JH.
    Int J Surg Pathol; 2007 Apr 15; 15(2):98-109. PubMed ID: 17478762
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: relation with epidemiologic factors, histologic features and prognosis.
    Fernández Aceñero MJ, Farina González J, Arangoncillo Ballesteros P.
    Gen Diagn Pathol; 1997 Jun 15; 142(5-6):289-96. PubMed ID: 9228251
    [Abstract] [Full Text] [Related]

  • 6. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR, Limiti MR, Bari M, Zambenedetti P, Montagutti A, Ricci F, Pappagallo GL, Sartori D, Vinante O, Mingazzini PL.
    Breast Cancer Res Treat; 2007 Mar 15; 101(3):279-84. PubMed ID: 16835704
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
    Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H.
    Breast Cancer Res; 2004 Mar 15; 6(1):R24-30. PubMed ID: 14680497
    [Abstract] [Full Text] [Related]

  • 13. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P, Alm P, Olsson H, Heidebrecht HJ, Fernö M, Baldetorp B, Parwaresch R.
    Hum Pathol; 2001 Mar 12; 32(3):311-9. PubMed ID: 11274641
    [Abstract] [Full Text] [Related]

  • 17. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
    Beck T, Weller EE, Weikel W, Brumm C, Wilkens C, Knapstein PG.
    Gynecol Oncol; 1995 Apr 12; 57(1):96-104. PubMed ID: 7705708
    [Abstract] [Full Text] [Related]

  • 18. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E.
    Cancer; 2003 Mar 15; 97(6):1573-81. PubMed ID: 12627523
    [Abstract] [Full Text] [Related]

  • 19. Cysteine proteinase inhibitor cystatin A in breast cancer.
    Kuopio T, Kankaanranta A, Jalava P, Kronqvist P, Kotkansalo T, Weber E, Collan Y.
    Cancer Res; 1998 Feb 01; 58(3):432-6. PubMed ID: 9458085
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up.
    Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K.
    Clin Cancer Res; 2003 Feb 01; 9(2):716-21. PubMed ID: 12576440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.